<DOC>
	<DOCNO>NCT02873221</DOCNO>
	<brief_summary>This study evaluate long-term safety tolerability intermittent treatment ubrogepant acute treatment migraine 1 year .</brief_summary>
	<brief_title>An Extension Study Evaluate Long-Term Safety Tolerability Ubrogepant Treatment Migraine</brief_title>
	<detailed_description>Usual care open-label control arm . Dose ubrogepant ( 50 mg 100 mg ) double-blind active treatment arm .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Completed study UBRMD01 ( NCT02828020 ) UBRMD02 ( NCT02867709 ) . Patients clinically significant electrocardiogram ( ECG ) , vital sign , physical exam , laboratory abnormality Requirement medication study list prohibit medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>